Clinical studies in the second line setting of advanced pancreatic cancer: Are we Making Any progress?

Journal of the Pancreas

Volumn 13, Issue 4, 2012, Pages 358-360

  Ramfidis, Vassilios S ^a   Strimpakos, Alexios S ^a   Syrigos, Kostas N ^a   Saif, Muhammad W ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Drug therapy; Pancreatic Neoplasms

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN; SUNITINIB; TRABEDERSEN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIC ENTEROCOLITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PROGRESSION FREE SURVIVAL; SOLID TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; QUINAZOLINES; THIONUCLEOTIDES;

EID: 84864508092     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13.
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 May 20;25(15):1960-6.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.
4. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676-81. Epub 2011 May 10.
5. Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A et al. Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial (NCT00967603). J Clin Oncol 2012; 30(Suppl):Abstract 4017.
6. Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ at al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011 Jun;102(6):1193-200. Epub 2011 Mar 30.
7. Oettle H, Seufferlein T, Luger T, Schmid RM, von Wichert G, Endlicher E, Garbe C, Kaehler KK, Enk A, Schneider A, Rothhammer-Hampl T, Grosser S, et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol 2012; 30(Suppl):Abstract 4034.
8. Stieler J, Pelzer U, Sinn M, KaetheStriefler J, Dörken B, Riess H. CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5- FU) (24h) in combination with lapatinib as second-line therapy in pancreatic cancer after gemcitabine failure: A phase I trial. J Clin Oncol 2012; 30(Suppl):Abstract e14533.
9. Wu Z, Marshall J, JJ Hwang, MJ Pishvaian, A Wellstein, LM Weiner et al. A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer. J Clin Oncol 2012; 30(Suppl):Abstract e14569.